Comparison of Work Relative Value Units Assigned to Urological and Gynecological Surgical Procedures.

INTRODUCTION: We sought to determine if work relative value unit differences exist between analogous, sex-specific procedures. METHODS: Representatives from the AUA and the American College of Obstetricians and Gynecologists independently reviewed the entire procedural code set and identified sex-specific procedures that had an analogous procedure in the opposite sex. These pairs were then evaluated and compared using current American Medical Association Relative Value Scale Update Committee methodology. Comparable code pair values were then examined to determine any systemic bias in the work relative value units assigned between the procedures. Mean differences and 95% confidence intervals were used to determine any differences in procedure or physician time values. The methodology used considered global period, intraservice time, total time, hospital days, postoperative office visits, and the date of the committee review. RESULTS: Of the 10 directly analogous code pairs reviewed, 7 of the female procedures had higher work relative value unit differences (range 0.29-6.47), and 3 of the male procedures had higher work relative value unit differences (range 1.23-2.34). There was no statistical difference between the code pair work relative value units. The work relative value unit per minute of intraservice time and total time were not statistically different. CONCLUSIONS: In this study, we compared operative procedures performed in women with clinically comparable operative procedures performed in men that had similar surgical approaches, global periods, and valuation methodologies. Overall, no statistical differences in work relative value units were demonstrated.

Robotic Sacral Colpopexy Using Autologous Fascia Lata Compared with Mesh.

Objective: The objective is to compare robotic sacral colpopexy (RSC) utilizing autologous fascia lata with RSC with synthetic mesh in the treatment of pelvic organ prolapse (POP). Methods: We performed a prospective nonrandomized case comparison trial at a single institution. We compared RSC utilizing either synthetic mesh or autologous fascia lata in women with symptomatic POP, stages II through IV. The primary outcome was anatomic prolapse recurrence determined by the Pelvic Organ Prolapse Quantification (POP-Q) examination. Secondary outcomes included patient-reported outcomes such as the Urogenital Distress Inventory-6 (UDI-6) and Incontinence Impact Questionnaire-7 (IIQ-7). Complications were also recorded and categorized using the Clavien-Dindo (CD) system. The hypothesis is that autologous fascia lata would provide equivalent anatomic and patient-reported outcomes compared with mesh while eliminating mesh-related complications. Results: Sixty-four women underwent RSC with 19 (29.7%) receiving fascia lata graft. The overall operative time was greater in the fascia lata group with mean fascia lata harvest time of 24.8 ± 7.4 minutes. Intragroup comparisons of the fascia and mesh groups demonstrated significant improvement in pelvic measurements as well as patient-reported outcomes. Intergroup comparison demonstrated equivalent success rates at 12.1 ± 8.7 months follow-up. There was one apical failure in the fascia lata RSC group; however, the difference was not statistically significant (p = 0.30). Significant complications in the fascia lata harvest group included two CD-II and one CD-IIIb. In the mesh group there was one mesh erosion requiring surgical excision (CD-IIIb). Conclusion: This is the first comparison between RSC with autologous fascia lata and mesh. Short-term anatomic outcomes were similar with autologous fascia lata use without the risk of mesh erosion. Morbidity from graft harvest site was not trivial. These results emphasize the need for a randomized controlled trial.

HPV: diagnosis, prevention, and treatment.

Human papilloma virus (HPV) is the most common sexually transmitted disease in the world. Almost 80% of the world's population is exposed by the age of 50. HPV can cause oropharyngeal, genital, and anal cancers. It also causes genital warts. There is no cure for HPV but vaccines are available to prevent infection by the most common HPV viruses; unfortunately, usage is low. Most people will clear HPV spontaneously. Those who do not are at high risk for developing malignancy. Treatment mainstays are destruction and excision of the lesions.

Is liquid-based pap testing affected by water-based lubricant?

OBJECTIVE: To estimate the effect of water-based lubricant on the liquid-based Pap test. METHODS: Two hundred women each had 2 simultaneous Pap test collections. One specimen was randomly contaminated with 0.5 mL of water-based lubricant after collection. The physician was blinded as to which collection was contaminated. Both specimens were sent for cytology. Cytopathologists were blinded to the study. The rate of abnormal cytology and discordance between the control and the contaminated specimens was estimated. The discordance of secondary diagnoses, such as yeast infections and bacterial vaginosis, was also estimated. RESULTS: The incidence of abnormal cytology was similar in the contaminated specimens and the control specimens (6.5%, 95% confidence interval [CI] 3.5-10.9% versus 7.0%, 95% CI 3.9-11.5%). The rate of disagreement between the 2 specimens collected from each patient was 7.5% (95% CI 4.6-12.1%) and is similar to previously published estimates of discordance using conventional cytology. Secondary diagnoses, such as yeast infections or bacterial vaginosis, were similar in both groups, suggesting no interference from the lubricant. CONCLUSION: Water-based lubricant does not affect liquid-based cervical cytology Pap testing. Water-based lubricant does not affect secondary diagnoses such as bacterial vaginosis or yeast infections. LEVEL OF EVIDENCE: II-1.

Intact genetic material is present in commercially processed cadaver allografts used for pubovaginal slings.

PURPOSE: We determined the presence, quantitated the concentration and assessed the length of DNA present in 4 commercially available human cadaver allografts. MATERIALS AND METHODS: We evaluated 10 tissue samples from each of 4 commercial sources of human allograft (Mentor Corp., Santa Barbara, California; Musculoskeletal Transplant Foundation, Edison, New Jersey; Regeneration Technologies, Inc., Alachua, Florida; and Life Cell Corp., Woodlands, Texas) for intact DNA segments. All allograft samples underwent a standard extraction technique (proteinase K/sodium dodecyl sulfate/phenol) to isolate genetic material. Spectrophotometry evaluation was done to quantify DNA concentrations. Polymerase chain reaction was performed to amplify the retrieved DNA material. Agarose gel electrophoresis was performed to determine the size of DNA fragments. RESULTS: Of the 49 samples tested from all 4 commercial sources of human allograft fascia 39 (97.5%) contained DNA of 400 to 2,000 bp segments. A 400 bp DNA segment was present in 9 Mentor, 10 Musculoskeletal Transplant Foundation, 10 Regeneration Technologies and 10 Life Cell samples. A 700 bp DNA segment was present in 10 Musculoskeletal Transplant Foundation, 10 Regeneration Technologies and 10 Life Cell allografts. A 2,000 bp DNA segment was present in 10 Life Cell tissues. CONCLUSIONS: Intact genetic material was present in all 4 commercially processed human allografts. Tissue processing did not completely eliminate intact DNA segments. The size of the intact DNA and the concentration of DNA varied widely based on tissue processing methods.